Our results also demonstrate the potential of targeting ligand–receptor pairs in HSC-Prog, such as CXCL2 and CXCL3 and their receptors CXCR1 and CXCR2, for AML diagnosis or treatment. This evidence concerns the gene CXCR1 and acute myeloid leukemia.